Diabetic Neuropathy Market Share

  • Report ID: 4526
  • Published Date: Jul 29, 2024
  • Report Format: PDF, PPT

Diabetic Neuropathy Market Share

North American Market Forecast

The North America diabetic neuropathy market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2036. The growth of the market can be attributed majorly to the rising prevalence of diabetes, the increasing geriatric population, and the growing healthcare expenditure on diabetes. As per the estimations of the American Diabetes Association in 2018, the total cost of diagnosed diabetes was USD 327 billion of which USD 237 billion was spent on direct medical costs and USD 90 billion on reduced productivity in the U.S. The aged population in the region and the rising concern of people and the government on their health increases the healthcare expenditure in the region. The government also initiated several camps to provide proper awareness and health care to the public. The rising disposable income and increasing penetration of the internet increased the early diagnosis visits in the region is projected to have a positive impact on the diabetic neuropathy market growth during the forecast period. Digitalization and improvement in the infrastructure of hospitals to provide good patient care increases healthcare expenditure and reduces the risk of disease prevalence. All these factors is projected to rise the growth of the global diabetic neuropathy market in the region.

Research Nester
Diabetic-Neuropathy-Market-Size
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 4526
  • Published Date: Jul 29, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of diabetic neuropathy is estimated at USD 5.85 Billion.

The diabetic neuropathy market size was valued at USD 5.43 Billion in 2023 and is poised to cross USD 15.67 Billion by the end of 2036, registering more than 8.5% CAGR during the forecast period i.e., between 2024-2036. Increasing cases of diabetes and a rising population are major factors driving the market growth.

North America industry is predicted to dominate largest revenue share by 2036, due to rising prevalence of diabetes along with increasing geriatric population, and the growing healthcare expenditure on diabetes in the region.

Hoffmann-La Roche Ltd., Abbott Laboratories, Eli Lilly and Company, Johnson & Johnson Services, Inc., GlaxoSmithKline plc, Lupin Limited, Glenmark Pharmaceuticals Limited, Assertio Holdings, Inc., Astellas Pharma US, Inc., Pfizer Inc.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying